Antibiotic selection based on novel microbiological principles
AtbFinder® — a fundamentally new rapid test to select effective antibiotics for the most hard-to-treat infections: antibiotic-resistant, relapsing, and persistent.
90-180 antibiotics
Per patient — ultra-broad antibiotic profiling
6-20 hours
from sample to results
01
AtbFinder® — Selects antibiotics under conditions mirroring each patient's infection environment.
02
Identifies therapies that works in the patient – not just in the lab
03
Finds effective antiobitic regimens effective antibiotic regimens when other fail
Clinically validated for personalized antibiotic selection in the most difficult-to-treat infections
100%
Clinical Response
100%
Eradication of chronic and relapsing infections
100%
Efficacy in antibiotic-resistant infections
Effective antibiotic therapy for any infection
Antibiotic-resistant (ESKAPE pathogens and superbugs)
Chronic and relapsing
Mixed bacterial-fungal
Biofilm-associated
Complicated UTIs
Catheter-associated infections
Pneumonia (VAP)
Hospital acquired infections
Cystic Fibrosis
Sepsis
Wound infections
"No option" patients
Antibiotic testing tailored to each patient
population for maximum precision:
Adults
Pediatrics
Special patient groups
- Immunosuppressed
- Cancer patients
- Autoimmune
- Elderly
How it works
01
Clinical sample collected from the site of infection
02
Testing antibiotics at concntrations achievable at the site of infection rather than relying on MIC-based thresholds.
03
Testing antibiotics at concentrations achievable at the infection site. Real-life antibiotic performance.
04
Shows which antibiotics actually kill the microbes
05
The test results provide a complete list of antibiotics that are effective. AtbFinder identifies which antibiotics will work for the patient's infection.
How it works
AtbFinder
Identifies antibiotics that target all microorganisms at the infection site.
AtbFinder
identifies antibiotics effective against microbial communities-biofilms
AtbFinder
AtbFinder is the only test that selects antibiotics based on concentrations that can be achieved at the site of infection.
Laboratory developed test
AtbFinder is an all-in-one proprietary laboratory-developed test which is processed in our first-in-class CLIA certified laboratory facility TX.
01
Sample collection
02
Shipment to Lab
03
AtbFinder testing
04
Results in 6-20 hours*
Unique metod
How AtbFinder selects antibiotics against antibiotic resistant microorganisms
01
Modulates real-life antibiotic performance individually in each patient
02
Antibiotics are tested at the cocntrations achieved at the site of infection
03
Against all microorganisms at the site of infection: Primary pathogens, Supporting microorganisms
Only AtbFinder maintains the patient-mediated microbial "memory" of all pathogens from the infection site, resulting in individualized, effective antibiotic therapy.
References
1
Tetz G, Tetz V. Evaluation of a New Culture-Based AtbFinder Test-System Employing a Novel Nutrient Medium for the Selection of Optimal Antibiotics for Critically Ill Patients with Polymicrobial Infections within 4 h. Microorganisms. 2021 May 4;9(5):990. doi: 10.3390/microorganisms9050990.
2
Tetz G, Kardava K, Vecherkovskaya M, Hahn A, Tsifansky M, Koumbourlis A, Tetz V. AtbFinder Diagnostic Test System Improves Optimal Selection of Antibiotic Therapy in Persons with Cystic Fibrosis. J Clin Microbiol. 2023 Jan 26;61(1):e0155822. doi: 10.1128/jcm.01558-22.
3
Tetz GV, Kardava KM, Vecherkovskaya MF, Tsifansky MD, Tetz VV. Treatment of chronic relapsing urinary tract infection with antibiotics selected by AtbFinder. Urol Case Rep. 2022 Dec 28;46:102312. doi: 10.1016/j.eucr.2022.102312. 2026 ASCO Annual Meeting New Paradigm for Antibiotic Selection in Hard-to-Treat Drug-Resistant Infections Following HSCT
AUA 2026
AtbFinder: A Novel Diagnostic Test That Improves Antibiotic Selection and Clinical Outcomes in UTI-Associated Cognitive Decline and Delirium in Patients with Neurodegenerative Disorders
SIDP & MAD-ID Annual Meeting
Microbial Cell Memory in Biofilms: A New Frontier for Effective Antibiotic Selection in Hard-to-Treat Drug-Resistant Infections